TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Propanolol in Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18- 65~* diagnosis of stage I-III breast cancer , confirmed by a core biopsy~* Planning to undergo definitive surgery including mastectomy or breast conserving surgery~* Systolic blood pressure must be \>100 mmHg but no more than 140 mmHg and/or diastolic \> 60 mmHg and no more than 95 mmHg.~* normal baseline EKG~Exclusion criteria:~* Pregnancy; potential subjects of female bearing age will have to complete a pregnancy test during screening to ensure that they are not pregnant. Potential patients who are post-menopausal must have confirmed one year without menstrual cycle.~* Free of major medical illnesses including:~* Uncontrolled Diabetes (HbA1c of ≤ 8 if previously tested)~* Uncontrolled hypertension: BP \>systolic 140/ diastolic \> 95~* Cardiac diseases (history of cardiac valve disease, coronary artery disease, congestive heart failure, A-V block, peripheral vascular disease, any cardiac arrhythmia/bradycardia) with the exception of the diagnosed cancer.~* Histories of asthma, bronchospastic disease, or obstructive pulmonary disease~* Previously diagnosed thyrotoxicosis~* Severe allergic reactions to medications which are included in the beta blocker family~* Previously or currently treated with a beta adrenergic receptor antagonist~* Patients with locally advanced or inflammatory breast cancer not amenable to surgical resection~* Patients taking any of the following medications will be excluded:~  * Drugs that are categorized as digitalis glycosides, beta-blockers and calcium channel blockers, ACE inhibitors and alpha blockers~ * Amiodarone~ * Cimetidine~ * Ciprofloxacin~ * Delavudin~ * Dobutamine~ * Ethanol~ * Fluconazole~ * Fluoxetine~ * Fluvoxamine~ * Haloperidol~ * Imipramine~ * Isoniazid~ * Isoproterenol~ * Luvoxamine~ * Paroxetine~ * Phenytoin~ * Phenobarbital.~ * Propafenone.~ * Quinidine~ * Reserpine~ * Rifampin~ * Ritonavir~ * Rizatriptan.~ * Tenioposide~ * Theophylline~ * Thyroxine~ * Tolbutamide.~ * Warfarin~ * Zileuton~ * Zolmitriptan

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- open label single arm, drug propanolol (Type: EXPERIMENTAL): all subjects will receive the experimental drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 yrs~* consent obtained~* septic shock (according to international definition)~* patient sedated and submitted to invasive mechanical ventilation~* no need for surgery expected within 24 hours after enrollment~* patient has received at least one dose of large spectrum antibiotics~* superior vena cava catheter in place~* patient carrying a thermodilution device for cardiac output measurement~* stable mean arterial pressure within 65-5 mmHg limits for at least 2 hours;~Exclusion Criteria:~* pregnancy~* age below 18 years~* patient treated with iv continuous epinephrine~* chronic occlusive arteriopathy of the upper limbs~* regular or recent treatment with glibenclamide or glipizide~* regular or recent treatment with steroids~* known surrenal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): 10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
- hydrocortison (Type: ACTIVE_COMPARATOR): 50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Is 18 years or older; male or female.~2. Previous diagnosis of venous insufficiency proven by a positive venous duplex with reflux.~3. Has a venous ulcer with a wound area between 5 cm2 - 40 cm2.~4. Has an ankle brachial index (ABI) \>0.8.~5. Has a venous ulcer with duration less than 24 months.~6. Has a venous ulcer which is critically colonized (not infected) based on the Lazareth Study Model. Ulcers are considered to be critically colonized if at least three of the five following signs are present:~   Severe spontaneous pain between two dressing changes,Perilesional erythema,Local edema,Malodour,Heavy Exudation~7. Is currently using Profore as their standard of care.~8. Has not received antibiotics for 6 weeks prior to enrollment.~Exclusion Criteria~1. Has an allergy to one of the components of the dressings (calcium alginate, hydrocolloid \[carboxymethylceullose\], silver).~2. Is currently on antibiotics.~3. Has a negative venous duplex.~4. Is unable to tolerate 4 layer compression.~5. Is unable to continue contact with the investigator for a period of at least two weeks.~6. Is unwilling or unable to comply with the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Restore Calcium Alginate Dressing Silver (Type: EXPERIMENTAL): Restore Calcium Alginate Dressing Silver under compression wrap
- Aquacel Ag Wound Dressing (Type: ACTIVE_COMPARATOR): Aquacel Ag Wound Dressing under compression wrap

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Early Musical Intervention on Prevalence and Severity of Paroxysmal Sympathetic Hyperactivity After Severe Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe traumatic brain injury (either initial Glasgow Coma Scale \< 8 or intracranial pressure \> 20mmHg for more than 20 min)~* National health service coverage~* Informed consent signed by next of kin~Exclusion Criteria:~* Non-traumatic brain injury~* Conditions interfering with measures: bilateral fixed pupils, temporal bone fracture including acoustic channel, eye trauma, previous eye surgery, otorrhagia, hypoacusis,~* Preexisting autonomic nervous system imbalance: severe diabetes, arrhythmias, pace maker, implantable defibrillator, cardiac transplantation~* Respiratory rate \< 9/min~* Patient subject to guardianship or wardship~* Pregnant or breastfeeding woman~* Current participation in another biomedical research protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Musical intervention (Type: EXPERIMENTAL): Music is provided through headphones: Two 30-min musical sessions per day (one in the morning and one in the evening) beginning at the onset of desedation (Day 0) until day 21.~Both have inverted U shape.
- Control (Type: SHAM_COMPARATOR): Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Flexible Thoracolumbar Brace on Idiopathic Scoliosis, Prospective, Randomized, Open-label Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* who have idiopathic scoliosis, showing at Cobb's angle over 20 degrees,less than 45 on X-ray~Exclusion Criteria:~* Patients who underwent spinal surgery~* Patients with spinal scoliosis due to cerebral palsy, muscle paralysis, polio, congenital spinal abnormalities~* Patients observed with Cobb's angle less than 20 degrees, over 45 degrees~* Patients complaining of acute low back pain~* Patients with cognitive impairment, severe mental illness, and inability to communicate

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- scoliosis patients (Type: EXPERIMENTAL): scoliosis patients who have cobb angle over 20 degree wear scoliosis brace for six months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Rapid Sequence Intubation (RSI) Drug Delivery Using Intraosseous (IO) and Intravenous (IV) Access.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Requires rapid sequence intubation~* Succinylcholine is chosen paralytic agent~* IV or IO access has been established for rapid sequence intubation~* For IV access patients, their rapid sequence intubation case is the next occurring IV rapid sequence intubation case following an enrolled IO RSI case.~Exclusion Criteria:~* Vascular access other than IV or IO has been established

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous (IV) drug delivery (Type: None): patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
- Intraosseous (IO) drug delivery (Type: None): Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mid-turbinate nasal swab collected for SARS-CoV-2 RT-PCR at the same time of CoviDx Rapid Antigen swab collection~* Symptomatic subjects suspected of having COVID-19, first onset of COVID-19-like symptoms (e.g., chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea) should not have started more than 5 days from the time of the study visit. Symptoms must be present on the day of CoviDx testing.~* ≥ 2 years of age~* Participants between 2-13 years of age, inclusive, must participate with a guardian who will be collecting the swab.~* Signed Informed Consent~Exclusion Criteria:~* Participants with prior medical or laboratory training~* Unable or unwilling to provide signed, Informed Consent~* Less than 2 years of age~* Received a positive diagnostic test result for COVID-19 in the past 14 days~* Received a negative diagnostic test result for COVID-19 in the last 18 hours~* Study Comparator collection that occurred \> 3 hours from CoviDx swab collection~* For symptomatic participants: first onset of COVID-19-like symptoms occurring more than 5 days from study visit~* Invalid or missing study comparator test results~* Use of a non-high-sensitive SARS-CoV-2 test as the comparator SARS-CoV-2 RT-PCR test (e.g., rapid molecular, rapid antigen tests, tests that do not have FDA EUA, a test that was not approved by Sponsor for use in the study)~* Enrollment in another study involving the collection of a nasopharyngeal, mid-turbinate nasal swab or anterior nasal swab within 6 hours of CoviDx testing.~* Indicates they would not use a COVID-19 diagnostic test kit in real life~* Taking any of the following medications or treatments within 7 days of study visit (antivirals (e.g., Remdesivir, Paxlovid) and/or monoclonal antibodies (e.g., REGEN-COV (casirivimab, imdevimab), Sotrovimab (Xevudy), Evusheld)~* Nasal spray administration in the last 48 hours

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SARS COv-2 RT-PCR AND Self collected CoviDx Covid-19 Antigen Self-Test (Type: None): Sequentially enrolled symptomatic patients will have a nasal swab collected for high-sensitive SARS-CoV-2 RT-PCR testing as comparator and self collect a nasal swab for CoviDx™ Covid-19 Antigen self-testing. Order of tests will be performed following a randomization scheme.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been implanted with an Accent MRI pacemaker and Tendril MRI leads.~* Have an RV lead implanted apically (group A) or septally (Group B)~* Are RV paced for \<50% of the time (groups A2 and B2)~* Are RV paced for \> 50% of the time (Groups A1 and B1)~* Are ≥ 18 years of age.~* Are able to provide written informed consent.~* Are willing and able to comply with the prescribed follow-up tests and schedule of evaluations.~Exclusion Criteria:~* Have permanent atrial fibrillation with preserved intrinsic conduction~* Have a non-MRI compatible device or material implant (e.g., intracranial aneurysm clip, non-MRI compatible devices or material, metals or alloys, etc.).~* Have a lead extender, plug or adaptor.~* Do not have an RV lead implanted apically or septally.~* Are eligible for groups A1 or B1 but appropriate group already has 20 patients enrolled.~* Are eligible for groups A2 or B2 but appropriate group already has 5 patients enrolled~* Are currently participating in another device or drug investigation which includes an active treatment arm.~* Are pregnant or planning to become pregnant during the duration of the study.~* Have a life expectancy of less than 12 months from Screening due to any life-threatening condition.~* Are contraindicated for an MRI scan due to any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Septal RV lead with >50% pacing (B1) (Type: EXPERIMENTAL): Cardiac MRI with pacemaker stimulation
- Septal RV lead with <50% pacing (B2) (Type: EXPERIMENTAL): Cardiac MRI with and without pacemaker stimulation
- Apical RV lead with >50% pacing (A1) (Type: EXPERIMENTAL): Cardiac MRI with pacemaker stimulation
- Apical RV lead with <50% pacing (A2) (Type: EXPERIMENTAL): Cardiac MRI with and without pacemaker stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing CT Scan and Stress Test in Patients With Known Coronary Artery Disease Hospitalized for Chest Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient admitted for chest pain / pressure or other suggestive symptoms~* patient has known coronary artery disease (with or without prior revascularization)~* patient has clinical need for non-invasive cardiac evaluation~Exclusion Criteria:~* evidence of ongoing myocardial infarction or hemodynamic instability~* ischemia on EKG (greater than 1mm ST segment deviation)~* contraindications to CT scanning with iodinated intravenous contrast (including allergies, asthma and renal dysfunction)~* heart rhythm precluding EKG gating~* pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Initial coronary CT angiography (Type: EXPERIMENTAL): EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
- Initial nuclear stress test (Type: ACTIVE_COMPARATOR): Stress radionuclide myocardial perfusion imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intrapartum Glycemic Control in GDMA2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 years or older~* Non-anomalous singleton gestation~* Gestational diabetes type A2 diagnosed at 24 weeks' gestation or beyond~* Planned vaginal delivery at term at Inova Fairfax Women's Hospital~Exclusion Criteria:~* Women \< 18 years~* Fetus with major congenital malformations~* Twin or higher order gestation~* Pre-existing diabetes mellitus~* Exposure to antenatal or any systemic steroids 14 days or less prior to delivery~* Preterm delivery~* Scheduled cesarean birth~* Intrapartum cesarean birth prior to 4-5 cm of cervical dilatation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Usual care glycemic management arm (Type: ACTIVE_COMPARATOR): Blood glucose will be checked every 2 hours during labor and glucose target will be 75-110 mg/dl
- More liberalized glycemic management arm (Type: ACTIVE_COMPARATOR): Blood glucose will be checked every 4 hours during labor and glucose target will be 70-126 mg/dl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologically Confirmed Glioma after completion of planned biopsy or resection.~   High grade glioma histologies:~  * Glioblastoma~  * High Grade or Malignant Glioma~  * Anaplastic Astrocytoma~  * Anaplastic Oligodendroglioma~  * Gliosarcoma~  * Mixture of any of the above histologies Low Grade Histologies~  * Astrocytoma~  * Grade II or low grade glioma~  * Oligodendroglioma~  * Mixtures of the above histologies~2. Plan to undergo external radiation treatment as part of therapy~3. No prior therapeutic cranial radiotherapy~4. Can safely perform clinically indicated MRI (no contraindications to MRI with Gadolinium) as determined by the standard Johns Hopkins Radiation Oncology screening procedures,~Exclusion Criteria:~1. Patients who cannot undergo MRIs.~2. Patients who are allergic to gadolinium based contrast agent~3. Patients who have cardiac pacemaker or other electronic or metal implant~4. Patients who have chronic kidney disease judged sufficient to exclude them from the clinically indicated contrast enhanced MRI.~5. Female patients who is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- APT MRI (Type: EXPERIMENTAL): Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.~1. Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.~2. An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.~3. Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* individuals diagnosed with Graves' disease undergoing total thyroidectomy for cure of disease.~Exclusion Criteria:~* no Graves' disease~* \< 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SSKI (Potassium Iodide) (Type: ACTIVE_COMPARATOR): Participants randomized to receive 7 days of pre-operative SSKI
- NO SSKI (Type: NO_INTERVENTION): Participants randomized to not receive any drug pre-operative

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues